Skip to main content

Table 2 Subgroup analyses for the effect on the blood glucose

From: Association between ICS use and risk of hyperglycemia in COPD patients: systematic review and meta-analysis

Subgroup title

No of trials

No of participants

Risk ratio (95% CI)

P Value

I2 (%)

Overall

6

8216

1.20 (0.79–1.82)

0.40

0

Daily dose

     

 Low dose

2

1949

1.20 (0.66–2.20)

0.53

22.3

 Medium dose

2

4170

1.19 (0.72–1.95)

0.50

28.3

 High dose

2

2097

1.38 (0.80–2.40)

0.25

0

Duration

     

 Less than 24 weeks

1

1620

1.01(0.29–3.48)

0.99

 

 At least 24 weeks

5

6596

1.22 (0.78–1.91)

0.37

30.3